CIK 0001604821 · Large accelerated filer
Natera, Inc.
Sign in to watch- Ticker
- NTRA
- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 010894487
- Phone
- 650-249-9090
- Business address
- 13011 MCCALLEN PASS, BUILDING A SUITE 100, AUSTIN, TX, 78753
- Former names
- Natera, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $104,832,418
- in 28 filings, $104.8M under 10b5-1 plans
Net −$104,832,418. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Rabinowitz Matthew −$72.3M EXECUTIVE CHAIRMAN sold 9% of stake
- Sheena Jonathan −$13.8M Director sold 83% of stake
- Moshkevich Solomon −$9.5M PRESIDENT, CLINICALDIAGNOSTICS sold 21% of stake
- Chapman Steven Leonard −$5.0M CEO AND PRESIDENT sold 12% of stake
- Brophy Michael Burkes −$2.5M CHIEF FINANCIAL OFFICER sold 11% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-07-16 | Sheena Jonathan Director | Sale 10b5-1 | −3,070 | $149.96 | $460K | 245,704 |
| 2025-07-02 | Sheena Jonathan Director | Sale 10b5-1 | −200 | $159.23 | $32K | 37,082 |
| 2025-07-02 | Sheena Jonathan Director | Sale 10b5-1 | −1,092 | $160.11 | $175K | 35,990 |
| 2025-07-02 | Sheena Jonathan Director | Sale 10b5-1 | −208 | $161.23 | $34K | 35,782 |
| 2025-07-02 | Sheena Jonathan Director | Sale 10b5-1 | −300 | $159.14 | $48K | 36,982 |
| 2025-07-02 | Sheena Jonathan Director | Sale 10b5-1 | −1,011 | $160.11 | $162K | 35,971 |
| 2025-07-02 | Sheena Jonathan Director | Sale 10b5-1 | −189 | $161.29 | $30K | 35,782 |
| 2025-07-01 | Chapman Steven Leonard CEO AND PRESIDENT | Sale 10b5-1 | −1,008 | $164.00 | $165K | 178,063 |
| 2025-07-01 | Chapman Steven Leonard CEO AND PRESIDENT | Sale 10b5-1 | −500 | $165.83 | $83K | 177,563 |
| 2025-07-01 | Chapman Steven Leonard CEO AND PRESIDENT | Sale 10b5-1 | −3,187 | $167.19 | $533K | 174,376 |
| 2025-07-01 | Chapman Steven Leonard CEO AND PRESIDENT | Sale 10b5-1 | −648 | $167.77 | $109K | 173,728 |
| 2025-07-01 | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | Sale 10b5-1 | −400 | $163.88 | $66K | 132,805 |
| 2025-07-01 | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | Sale 10b5-1 | −200 | $165.99 | $33K | 132,605 |
| 2025-07-01 | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | Sale 10b5-1 | −2,109 | $167.25 | $353K | 130,496 |
| 2025-07-01 | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | Sale 10b5-1 | −291 | $167.79 | $49K | 130,205 |
| 2025-07-01 | Marcus Gail Boxer Director | Option exercise 10b5-1 | +4,299 | $24.42 | $105K | 12,417 |
| 2025-07-01 | Marcus Gail Boxer Director | Sale 10b5-1 | −1,648 | $167.05 | $275K | 10,769 |
| 2025-07-01 | Marcus Gail Boxer Director | Sale 10b5-1 | −2,651 | $167.56 | $444K | 8,118 |
| 2025-07-01 | Marcus Gail Boxer Director | Option exercise · Stock Option (right to buy) 10b5-1 | −4,299 | 0 | ||
| 2025-06-27 | Chapman Rowan E Director | Grant or award | +2,143 | 8,345 |
Page 43 of 55 · 1,093 trades